Download Free 2nd International Symposium Drug Resistance In Leukemia And Lymphoma March 6 8 1995 Amsterdam The Netherlands Book in PDF and EPUB Free Download. You can read online 2nd International Symposium Drug Resistance In Leukemia And Lymphoma March 6 8 1995 Amsterdam The Netherlands and write the review.

Millions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis ? 8,000 people dying daily ? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges.
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.
Gretchen Krueger's poignant narrative explores how doctors, families, and the public interpreted the experience of childhood cancer from the 1930s through the 1970s. Pairing the transformation of childhood cancer from killer to curable disease with the personal experiences of young patients and their families, Krueger illuminates the twin realities of hope and suffering. In this social history, each decade follows a family whose experience touches on key themes: possible causes, means and timing of detection, the search for curative treatment, the merit of alternative treatments, the decisions to pursue or halt therapy, the side effects of treatment, death and dying—and cure. Recounting the complex and sometimes contentious interactions among the families of children with cancer, medical researchers, physicians, advocacy organizations, the media, and policy makers, Krueger reveals that personal odyssey and clinical challenge are the simultaneous realities of childhood cancer. This engaging study will be of interest to historians, medical practitioners and researchers, and people whose lives have been altered by cancer.
Genetic susceptibility refers to how variations in a person’s genes increase or decrease his or her susceptibility to environmental factors, such as chemicals, radiation and lifestyle (diet and smoking). This volume will explore the latest findings in the area of genetic susceptibility to gastrointestinal cancers, focusing on molecular epidemiology, DNA repair, and gene-environment interactions to identify factors that affect the incidence of GI cancers. Topics will include germline susceptibility, including Mendelian patterns of inheritance and gene-environment interactions that lead to cancer etiology.
This monograph provides a comprehensive overview of recent advances in the field of vasopressin and oxytocin. In the summer of 1997, scientists from over 20 countries congregated in Montreal for the 1997 World Congress of Neurohypophysial Hormones, a conference that united the fields of vasopressin, neurohypophysis and oxytocin in a single joint meeting that gave rise to the present book. The organization of a joint meeting was prompted by several recent developments. Specifically the molecular characterization of the vasopressin/oxytocin receptor family made it mandatory to adopt an integrated view and to discuss the vasopressin/oxytocin ligand/receptor family as a whole. To ensure em phasis on novelty, the conference focused on advances made over the last two years and also included important contributions by scientists that had not previously been associated with the vasopressin/oxytocin field. Vasopressin and oxytocin are two neurohormones that exert a wide spectrum of cen tral and peripheral actions. Accordingly, the vasopressin/oxytocin field embraces a large number of different domains, ranging from neuroscience, endocrinology, and oncology to renal, reproductive, and cardiovascular physiology and pathology.
This practically oriented book provides an up-to-date overview of all significant aspects of the pathogenesis of sepsis and its management, including within the intensive care unit. Readers will find information on the involvement of the coagulation and endocrine systems during sepsis and on the use of biomarkers to diagnose sepsis and allow early intervention. International clinical practice guidelines for the management of sepsis are presented, and individual chapters focus on aspects such as fluid resuscitation, vasopressor therapy, response to multiorgan failure, antimicrobial therapy, and adjunctive immunotherapy. The closing section looks forward to the coming decade, discussing novel trial designs, sepsis in low- and middle-income countries, and emerging management approaches. The book is internatio nal in scope, with contributions from leading experts worldwide. It will be of value to residents and professionals/practitioners in the fields of infectious diseases and internal medicine, as well as to GPs and medical students.
With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients. This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.